iScience

Article

Differential conservation analysis identifies residues defining constitutive internalization in beta-adrenergic receptors

Graphical abstract



Highlights

- Evolutionary analysis of BARs identifies differentially conserved residues
- Mutation of residues in TM1 of B2AR to B1AR residues modify dimer conformation
- Two closely located and potentially co-evolved residues modulate basal endocytosis

Authors

Abigail Rose Walker, Berkay Selçuk, Ismail Erol, Serdar Durdağı, Aylin Carla Hanyaloglu, Ogün Adebali

Correspondence

a.hanyaloglu@imperial.ac.uk (A.C.H.), oadebali@sabanciuniv.edu (O.A.)

In brief

Neuroscience; Sensory neuroscience

Walker et al., 2026, iScience *29*, 115033
March 20, 2026
https://doi.org/10.1016/j.isci.2026.115033

CellPress

iScience

CellPress
OPEN ACCESS

Article

Differential conservation analysis identifies residues defining constitutive internalization in beta-adrenergic receptors

Abigail Rose Walker,[3,7] Berkay Selçuk,[1,7] Ismail Erol,[4] Serdar Durdağı,[5,6] Aylin Carla Hanyaloglu,[3,8,*] and Ogün Adebali[1,2,8,9,*]

[1]Molecular Biology, Genetics and Bioengineering Program, Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul 34956, Türkiye
[2]TÜBİTAK Research Institute for Fundamental Sciences, Gebze 41470, Türkiye
[3]Institute of Reproductive and Developmental Biology, Department Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, UK
[4]Department of Analytical Chemistry, School of Pharmacy, Bahçeşehir University, Istanbul 34353, Türkiye
[5]Molecular Therapy Laboratory, Department of Pharmaceutical Chemistry, School of Pharmacy, Bahçeşehir University, Istanbul 34353, Türkiye
[6]Lab for Innovative Drugs (Lab4IND), Computational Drug Design Center (HITMER), Bahcesehir University, Istanbul, Türkiye
[7]These authors contributed equally
[8]These authors contributed equally
[9]Lead contact
*Correspondence: a.hanyaloglu@imperial.ac.uk (A.C.H.), oadebali@sabanciuniv.edu (O.A.)
https://doi.org/10.1016/j.isci.2026.115033

SUMMARY

G protein-coupled receptors (GPCRs) are major drug targets and key regulators of cell signaling. The basis of functional diversification between individual GPCRs and families of GPCRs can be revealed by investigating evolutionary conservation patterns. In this study, we investigated the functional role of specifically conserved residues in the TM1/TM7/H8 dimerization interface of beta-adrenergic receptors (BARs). Residues specifically conserved for B2AR compared to B1AR and B3AR subtypes were identified via phylogenetic analysis. The significance of residues differentially conserved between receptor subtypes at the TM1/TM1 interface was investigated using molecular dynamics (MD) simulations in combination with biophysical and functional studies. Our findings suggest that differentially conserved residues within TM1 of BARs modulate receptor conformation without disrupting dimerization to impact cell surface expression, basal activity, and endocytosis. This highlights the importance of TM1 in modulating receptor function and provides new insights into the evolutionary and functional differences among beta-adrenergic receptor subtypes.

INTRODUCTION

G protein-coupled receptors (GPCRs) are key regulators of cellular signaling and are responsible for a variety of physiological responses.[1] Due to their regulatory power and accessibility at the plasma membrane, they are major drug targets.[2] While the activity of GPCRs can be artificially influenced by drugs, they have also evolved multiple checkpoints to regulate their activation by endogenous ligands. These regulatory mechanisms ensure that misfolded receptors do not reach the cell membrane,[3–5] control signal specificity through G protein-coupling selectivity, and modulate sensitivity to external stimuli via receptor desensitization and internalization mediated through GPCR kinases and β-arrestins.[6–8] It has been shown that receptor dimerization plays a critical role in receptor maturation and internalization, in addition to modulating and diversifying signaling.[9,10] Despite the increased understanding of the mechanisms that drive functional diversity from GPCRs, how specificity shapes receptor activity from common mechanisms for an individual GPCR is poorly understood.

Throughout evolution, GPCRs have undergone functional diversification to facilitate cellular signaling. The basis of functional diversification can be revealed by investigating evolutionary conservation patterns. It is known that residues critical to receptor functions are typically resistant to mutations and conserved across orthologs, even those that are evolutionarily distant. Substitution of a residue at a homologous position in a paralogous receptor, while being conserved within its orthologs, indicates functional differentiation, such as an affinity for a distinct ligand or G protein.[11,12] The transmembrane (TM) core of GPCRs is highly conserved and thus a region to assess residues critical to function via differential conservation analysis. A GPCR property regulated by TM

domains is receptor dimerization. Among the various dimerization interfaces observed in GPCRs, identifying the most functionally relevant is important for understanding their contribution to receptor function and dynamics.[13] Experimental structures across Class A GPCRs suggest that interfaces involving TM1/TM2/helix 8 (H8) and TM3/4/5 are more frequently observed than other interfaces.[9,14–17] Comparison of these two interfaces via large-scale molecular dynamics (MD) simulations suggests that the TM1/TM2/H8 interface is more stable than the TM3/4/5 interface.[18]

The three human β-adrenergic receptor (BAR) subtypes, B1AR, B2AR, and B3AR, are class A GPCRs and share 51% sequence identity between Trp1.31 - Asp5.73 and Glu6.30-CysH8-Cterm, i.e., excluding the N- and C-termini and most of cytoplasmic loop 3. B1AR and B2AR have high structural and sequence similarity and are commonly used as models of GPCR function. While all BARs can couple to Gαs, there are clear differences in activity at a cellular and physiological level. B1AR and B2AR have distinct and often opposing roles in cardiac physiology and differ in their intracellular trafficking, ligand affinity, and propensity to form homomers.[19–22]

Structural data of the ligand-free turkey β1-adrenergic receptor (B1AR) and disulfide-trapping experiments indicate a role for the TM1/TM2/H8 interface.[23] These interaction sites within the TM domains may also impact additional functions, including biosynthetic receptor trafficking to the cell membrane for distinct GPCRs, including muscarinic M_1 acetylcholine receptor,[24] α_{2B}-adrenergic receptor, angiotensin II type 1A receptor,[25] and the B2AR.[26] Parmar et al. further suggested the existence of an ionic bond between TM1 and H8 that is crucial for proper receptor dimerization and sufficient cell surface expression in B2AR homodimers. In addition, single-molecule studies have demonstrated that ligand-free B2AR dimers interact with its heterotrimeric G protein Gαs to regulate its constitutive activity.[27] Overall, this suggests the intricate connection of distinct functional activities through these receptor-receptor interactions.

While previous studies have focused primarily on investigating loss-of-function rather than the exploration of the evolutionary rationale behind the differences in conserved interfaces and their effects on receptor activity, our goal is to investigate the functional significance of residues differentially conserved between BAR subtypes at the TM1/TM1 interface. To investigate BAR subtype-specific differences, we utilized a phylogenetic analytical platform that we previously developed to identify G protein interaction networks for the BARs,[11] aiming to pinpoint residues within a dimerization interface that are uniquely conserved for B2AR compared to B1AR and B3AR subtypes. We then mutated these residues to their B1AR and B3AR counterparts and assessed their impact on B2AR homodimerization, cell surface expression, cAMP signaling, and receptor internalization, including analysis by MD simulations. Our findings indicate that the mutation of specific residues within TM1 does not disrupt dimer interaction but may impact receptor-receptor conformations, highlighting distinct roles of these residues to increase or decrease basal activity. Overall, we argue for the existence of two co-evolved residues that regulate receptor internalization for aminergic receptors.

RESULTS

Evolutionary analysis of conserved interfaces in β-adrenergic receptor dimers

In order to investigate the impact of subtype-specific BAR residues on receptor dimerization, we utilized the structure of the turkey B1AR oligomer (PDB:4GPO).[23] Using the PISA (Proteins, Interfaces, Structures, and Assemblies) server (https://www.ebi.ac.uk/msd-srv/prot_int/pistart.html), we detected 24 residues within the TM1/TM7/H8 dimerization interface (Figure 1A).[28] Additionally, for each BAR subtype, we quantified the residue conservation at this interface by using MSAs of previously identified orthologs (Figure 1A middle section). At each column, we first identified the most frequent amino acid and then summed its count with the counts of all amino acids considered similar to this (BLOSUM80 > 1). Dividing this combined count by the total number of non-gap residues in the column gave the conservation percentage. In addition to these 24 residues, we also included F49$^{1.48}$ from B2AR as the 25th residue because it is conserved for B2AR and faces the dimerization interface. We used a stringent 90% conservation cutoff (except B1AR L70) and identified the most critical interface residues (Figure 1B**)**. We divided residues into two main categories: consensus and receptor-specific based on their conservation within orthologs and divergence across BAR subtypes. When all three receptors conserve a similar type of amino acid at the same position within their orthologs, we labeled that residue as consensus, indicating a shared function. On the other hand, when a receptor subtype conserves a non-similar amino acid unique to that subtype, we labeled that position as specifically conserved for that receptor, hinting at functional divergence. In total, our approach yielded six consensus and five specifically conserved residues. We demonstrated the positions of these residues on an experimental dimer structure. Residues L/M40 (B2AR residue numbers), V/I44, L/M45, P88, A91, and R333 were identified as consensus in our analysis. They are likely to play a critical role in the dimerization of all three BAR subtypes; however, for this study, we decided to focus on specifically conserved residues that could induce functional differentiation. Within five specifically conserved residues, we identified that B2AR conserves V/I34$^{1.33}$ with 97.30%, S41$^{1.40}$ with 98.65%, F49$^{1.48}$ with 98.65%, and E338$^{8.56}$ with 96.05%, while B3AR conserves R/K357 with 100% conservation percentage. We excluded E338$^{8.56}$ from our analysis because it was previously investigated by Parmar et al.[26]

Impact of mutating conserved B2AR residues to β1-adrenergic receptor/B3AR on receptor-receptor interactions

To understand the differential role of the specifically conserved residues at the dimerization interface, we chose B2AR, the best studied of the BARs. We used site-directed mutagenesis to create a B2AR with B1AR/B3AR mutants V34A$^{1.33}$, S41A$^{1.40}$, V34A/S41A, and F49A$^{1.48}$ and elucidate differences in the functional evolution of these receptors. Although all residues were mutated to alanine, the mutations were not intended to be disrupting mutations for a dimer interaction but reflected changes to the B1AR/B3AR sequence. To assess the impact

A



B

$$\text{Conservation \%} = \frac{\text{Most Frequent AA Count + Similar AA Count}}{\text{Non-Gap Count}}$$

	B1AR Turkey	(70 Orthologs) B1AR	(74 Orthologs) B2AR	(67 Orthologs) B3AR	Annotation
TM1	A42$^{1.33}$	A59 79.69%	V/I34 97.30%	A37 58.82%	B2 Specific
	M48$^{1.39}$	M/L65 98.53%	M/L40 100.00%	L/M44 92.31%	Consensus
	A49$^{1.40}$	A66 76.47%	S41 98.65%	A45 65.62%	B2 Specific
	V52$^{1.43}$	V/I69 98.53%	V/I44 100.00%	V/I48 96.36%	Consensus
	L53$^{1.44}$	L/M70 89.71%	L45 97.30%	L/M49 96.92%	Consensus
	A57$^{1.48}$	A74 67.65%	F49 98.65%	G53 64.62%	B2 Specific
TM2	P96$^{2.59}$	P113 100.00%	P88 100.00%	P92 98.51%	Consensus
	A99$^{2.62}$	A116 100.00%	A91 100.00%	A95 97.01%	Consensus
H8	R350$^{8.51}$	R/K384 96.97%	R333 98.68%	R353 100.00%	Consensus
	K354$^{8.55}$	Q388 51.52%	Q337 84.21%	R/K357 100.00%	B3 Specific
	R355$^{8.56}$	R389 93.94%	E338 96.05%	R/K358 83.08%	B2 Specific



Figure 1. Evolutionary analysis reveals consensus and specifically conserved residues at the dimerization interface

(A) The phylogenetic tree depicts the diversification of the B1AR, B2AR, and B3AR subtypes. The residue conservation analysis of the 24 residues within the TM1/TM7/H8 dimerization interface shows the sequence alignment and conserved residues across these subtypes. The schematic on the right illustrates the predicted dimerization interfaces within the transmembrane helices, highlighting receptor-specific conserved residues (marked with red dots).

(B) Table for the consensus and specifically conserved residues. For the positions at the dimerization interface, conserved amino acid(s), residue number, and conservation percentages are shown. The number of orthologs used for the calculation of conservation percentages is shown at the top. Annotation column indicates if a position is shared across all BAR subtypes (consensus) or specific to a receptor subtype (specifically conserved). Dimerization interface observed in turkey B1AR (PDB ID: 4GPO). B2AR-specific positions are represented by red spheres, and B3AR-specific positions are represented by blue spheres. Three residues chosen for further experimental analysis are labeled.

of the mutations on B2AR homodimerization, we employed bioluminescence resonance energy transfer (BRET) in HEK 293 cells transiently transfected with Rluc8-tagged B2AR and increasing amounts of Venus-tagged B2AR (Figure 2A). The $BRET_{50}$, a measure of receptor-receptor affinity, and $BRET_{max}$, a measure of the distance between receptors, were determined from BRET saturation curves (Figures 2B and 2C). Consistent with previous reports on the ability of B2AR to dimerize, the wildtype (WT) B2AR exhibited saturation in the BRET signal (Figure 2D). Cells expressing B2AR S41A$^{1.40}$ exhibited a small but significant decrease in $BRET_{50}$, suggesting an increase in the affinity or stability of this interaction (Figure 2D). V34A$^{1.33}$ exhibited a significantly lower $BRET_{max}$ and $BRET_{50}$, indicating both an increase in the distance between protomer tags and a higher affinity, overall suggesting a conformational rearrangement within this complex. This can either indicate the utilization of a different interface or adjustments to the existing interface, leading to increased distance between protomer tags. Interestingly, the double mutant exhibited a similar BRET interaction profile to the WT receptor, suggesting this double mutant "rescued" the conformational changes observed in the individual mutants. These results indicate that while these residues in the TM1 interface are not essential for B2AR homomeric interactions, they modulate the molecular arrangement of these associations.

Subsequently, we performed molecular dynamics (MD) simulations using the inactive state of the receptor to assess the strength of the interactions across different mutants. We used the interface observed in the crystal structure of the turkey B1AR[23] as our template due to its evolutionary proximity to B2AR and superimposed two inactive B2AR structures. We performed 5 replicates of 500 ns all-atom MD simulations for each mutant and looked at the total interaction strength by using a residue-residue contact score (RRCS) algorithm.[29] For each residue pair in the dimerization interface, we calculated interface contact scores and summed all the contact scores to calculate the interface contact scores for a given simulation frame. For each simulation, we retrieved 11 frames with 50 ns intervals and calculated the interface contact score between the protomers, resulting in 55 data points for each mutant. We compared interface contact score distributions between mutants to understand the impact of substitutions on dimer strength. As a result, we observed that simulations with the V34A$^{1.33}$ mutation exhibit the lowest median interface contact score, and this score was significantly lower compared to WT, S41A$^{1.40}$, and F49A$^{1.48}$ mutants (Figure 3). This supports the rearrangement of the



Figure 2. B2AR V34A$^{1.33}$ and S41A$^{1.40}$ mutations alter the organization of receptor homomers

(A) Schematic showing the experimental design of BRET for receptor-receptor associations. HEK 293 cells were transiently transfected with equal amounts of Rluc8-tagged receptor, either wild-type or with mutations, and increasing amounts of Venus-tagged receptor, either wild-type or with mutations. BRET saturation curves were used to determine the (B) $BRET_{max}$ and (C) the $BRET_{50}$. Data are the mean ± SEM; one-sample t test: *$p < 0.05$.

(D) Curve plotted using one-site specific binding saturation equation, representative curves shown, n = 6–8.

V34A$^{1.33}$ homomers and rescue of the BRET signal observed in the double mutant *in vitro* (Figure 2). While S41A$^{1.40}$ simulations exhibit a higher average interface contact score, it is not enough to create a statistically significant difference. We further validated the decrease in dimer strength observed in the V34A$^{1.33}$ mutation by performing MM-GBSA calculations to estimate the change in binding free energy (ΔG). In agreement with our RRCS analysis, V34A$^{1.33}$ leads to increased ΔG, indicating weaker dimerization, while the double mutant recovers to WT levels (Table S1). Detailed residue-level analysis revealed that V34A$^{1.33}$ lowers the binding contributions of neighboring TM1 residues, V31$^{1.30}$, V33$^{1.32}$, G37$^{1.37}$, I38$^{1.38}$, S41$^{1.40}$, L42$^{1.41}$, and L45$^{1.44}$, consistent with the observed loss of overall dimer affinity (Tables S2 and S3).

Although the residues selected do not involve important activation motifs, given the alterations in receptor dimerization, we assessed the ability of mutant receptors to activate the classical signaling pathway of B2AR – the Gαs/AC/cAMP pathway. HEK 293 cells transiently transfected with WT or mutant receptors were treated with increasing concentrations of B2AR agonist, isoproterenol. There was no difference in either the maximal response to agonist stimulation or the EC_{50} across receptors (Figures 4A and 4B). However, basal levels of cAMP production were significantly decreased ($p < 0.05$) in cells expressing the double mutant (Figure 4C). Based on these results, we can conclude that although we have observed changes in di/oligomerization dynamics of V34A$^{1.33}$ and S41A$^{1.40}$ mutations individually, none of these mutations significantly altered agonist-dependent cAMP production.

Co-evolved residues in transmembrane 1 of B2AR regulate constitutive internalization without impacting ligand-induced activation

One role of B2AR dimerization, via interfaces involving TM1/H8, that has been proposed is efficient folding and plasma membrane surface expression.[26] To assess the impact of these mutations on cell surface expression, HEK 293 cells expressing HA-tagged receptors were labeled live with anti-HA antibody and measured by flow cytometry. We measured two parameters: the percentage of cells expressing the receptor (% gated) and the level of cell surface expression in those cells expressing the receptor (gated mean fluorescence). While F49A$^{1.48}$ cell surface expression was the same as WT, V34A$^{1.33}$ and S41A$^{1.40}$ exhibited very minor but significant reductions in cell surface expression and/or % cells expressing receptor (Figures 5A and 5B). Cells expressing the double mutant exhibited greater reductions in both the percent gated (percentage of cells expressing the receptor) and the gated mean fluorescence (level of cell surface expression in those cells expressing the receptor) when compared to WT. To understand if these changes were due to reductions in the total cellular expression of the B2AR double mutant, B2AR-Rluc8 WT or mutant constructs were expressed, and the luminescent signal was measured (Figure 5C). This revealed that there was no difference in the total cell expression between WT receptors and V34A$^{1.33}$ S41A$^{1.40}$, or V34A/S41A mutants. Surprisingly, there was a significant increase in the whole-cell expression of F49A$^{1.48}$ mutant receptors compared to WT (Figure 5C), despite there being no difference in plasma membrane expression (Figures 5A and 5B).



Figure 3. Comparison of interface contact score distributions of different mutants at the dimerization interface

Each data point represents the interface contact score for a receptor for a given MD simulation frame with a 50 ns interval. V34A simulations exhibit significantly lower (padj<0.01) interface contact scores than WT, S41A, and F49A (indicated by **), except the double mutant is indicated by "ns." One-way ANOVA followed by Tukey's honest significant difference (HSD) post-hoc test. ns: not significant, RRCS: Residue-Residue Contact Score. See also Tables S1, S2, S3.

To understand if the decrease in basal cAMP production is caused by lower plasma membrane expression of the double mutant, flow cytometry was used with decreasing concentrations of WT receptor transfected to engineer conditions where WT and double mutant cell surface expression levels were equal (Figure S1). Under such conditions, there were no significant differences in basal levels of cAMP (Figure 5D) nor agonist-mediated cAMP production (Figure 5E). This suggests that decreases in basal activity of the double mutant are due to its reduced cell surface expression.

To differentiate whether the changes in the cell surface expression of the double mutant were due to ER retention or enhanced constitutive internalization, cells were imaged under two conditions. Cells were either "fed" with antibody live to measure receptors at the cell surface and those constitutively internalizing via the endocytic pathway, or antibody incubation was completed after fixation and permeabilization, to measure the total pool of receptor which includes receptors in the biosynthetic and endocytic pathways (Figure 5F). Cells were then imaged via confocal microscopy. All WT and mutant receptors exhibited plasma membrane expression, with WT, V34A$^{1.33}$, and S41A$^{1.40}$ exhibiting no detectable constitutive internalization, as the presence of receptor localized in intracellular vesicles was visible only when the antibody was incubated post-fixation/internalization (Figure 5G). The double mutant exhibited greater constitutive internalization compared to WT, and there was a notable increase in intracellular F49A$^{1.48}$ receptor under conditions that would detect both endocytic and biosynthetic localized receptor (Figure 5G).

To quantify the increase in constitutive internalization for the double mutant observed qualitatively via confocal microscopy (Figure 5G), flow cytometry was performed to compare the constitutive internalization of the WT receptor, compared to the double mutant and the B1AR. B1AR was included as the double mutant residues were mutated to their B1AR versions, and has previously been demonstrated to display higher constitutive internalization compared to B2AR.[30,31] The double mutant demonstrated significantly higher levels of constitutive internalization compared to the WT, and similar to levels exhibited by B1AR (Figure 5H). Overall, our analysis suggests that the double mutation of two closely located and potentially co-evolved residues at TM1 may have a role in regulating constitutive internalization.

DISCUSSION

In this study, we applied an evolutionary biological approach to uncover differential conservation patterns within the dimerization interface of BARs and investigated their impact on receptor dimerization, trafficking, and activation (Figure 6). Our studies revealed that while these residues within the putative TM1 dimer interface were not required for B2AR dimerization, they differentially impact B2AR activity, interestingly, all within the basal/ligand-independent state, with some gaining B1AR-like properties. Collectively, this data may highlight the complex and divergent roles of putative BAR dimer interfaces, and in turn is consistent with emerging data that highlights the multiple conformational states a GPCR can adopt, including prior to ligand binding.

MD simulations revealed critical insights into B2AR dimerization, particularly highlighting the role of specific residues (i.e., V34$^{1.33}$ and S41$^{1.40}$). These findings underscore the importance of specific residues in GPCR dimerization and suggest potential targets for modulating receptor function in therapeutic contexts. Our analysis further suggests a coevolution between B2AR residues V34$^{1.33}$ and S41$^{1.40}$. This claim is supported by two main lines of evidence. First, other aminergic receptors DRD1, 5HT4R, 5HT1D, and HRH4 (Table S4) also conserve valine/isoleucine and serine at the homologous positions. Second, when we induced the double mutation, we observed a restoration of receptor proximity and affinity compared to the V34A$^{1.33}$ mutation alone. This suggests that the S41A$^{1.40}$ mutation acts as a balancing factor that strengthens the functional association between these two residues. Overall, our findings highlight the importance of differentially conserved amino acids within the TM1/7/H8 interface in the regulation of dimer dynamics and receptor trafficking. For the remaining residues at the dimerization interface (Figure 1B), two are specifically conserved for B2AR (E338$^{8.56}$) and B3AR (R357$^{8.55}$), and six are shared across all three BAR subtypes, suggesting a common mechanism. While E338$^{8.56}$ for B2AR was previously suggested to be involved in salt bridge formation and regulate cell surface expression,[26] the role of R357$^{8.55}$ in B3AR needs to be explored in future studies.

In addition, we assessed if there were changes in receptor activation by measuring constitutive and ligand-induced cAMP signaling. Although we found no significant differences



D

B2AR	EC_{50}	EC_{50} 95% CI
Wild-type	1.26 nM	348 pM to 12.47 nM
F49A	623 pM	110 pM to 7.17 nM
S41A	654 nM	122 pM to 6.51 nM
V34A	704 pM	106 pM to 12.85 nM
V34A-S41A	3.03 nM	600.50 pM to 23.97 nM

Figure 4. The effect of B2AR mutations on basal and ligand-induced cAMP

(A) cAMP accumulation in HEK 293 cells transiently transfected with HA-B2AR WT and mutants with isoproterenol treatment (1 pM-10 μM, 5-min).

(B) cAMP production at the maximum isoproterenol dose (10 μM) and (C) basal cAMP production. Data are the mean ± SEM from n = 5–6 independent experiments. One-sample *t* test: ***$p < 0.001$.

(D) EC_{50} values for curves in Figure 4A.

in agonist-induced cAMP signaling across the mutants, the double mutation decreased basal levels of cAMP production due to lowered surface expression. Previous reports have demonstrated a significant receptor reserve for BARs in the human heart, with only 8–25% of receptors requiring occupation to reach half of the maximal response.[32] This highly saturable system may account for why we detect no difference in agonist-induced cAMP production between mutants, including when we matched the expression of the double mutant to the WT receptor and still observed no differences in ligand-induced cAMP signaling. Nonetheless, the data show that none of the mutants interfered with the activation mechanism of B2AR despite the alteration of dimerization dynamics. GPCRs can also activate Gαs/cAMP signaling from intracellular compartments, including early endosomes.[33] In addition to the plasma membrane, B2AR elicits a "second wave" of cAMP signaling via early endosomes, and these compartmentalized signals are responsible for specific outcomes.[33,34] One interpretation of our data is that plasma membrane and not the endosomal localization of B2AR is important for basal activity. Thus, V34/S41 residues may either have distinct roles in controlling basal G protein signaling and constitutive internalization, or these processes are interlinked.

BRET and MD simulation data combined suggest that mutant B2AR dimers are not disrupted but are altered in conformation. For some mutants, e.g., S41A, a small increase in protomer affinity only was observed via BRET with a statistically non-significant increase in interface contact score via MD simulation studies, however these changes may be due to BRET assessing interactions across multiple cellular compartments and thus may reflect altered subcellular factors, e.g., lipid environment, that are not included in the simulations performed in this study. Although similar TMs are implicated, the dimer interface for B1AR and B2AR is reported to be slightly different; thus, it is perhaps unsurprising that the full disruption of homomers is not measured as the mutants are likely promoting a more "B1AR-like" interface. Additionally, the literature suggests that the B2AR interface involves TM1 but can also include other TMs, so disrupting TM1 may not be sufficient to fully disrupt the dimer, as the complex may undergo modulation to favor other interfaces.[18] This is supported by the rolling dimer interface model, which suggests that dimers are highly dynamic and might sample multiple interfaces that co-exist and interconvert.[35]

It is unclear if the enhanced constitutive internalization for the double mutant is related to the dimer state. What this data does highlight is the conformational complexity of GPCRs at all stages of the GPCR life cycle and the spectrum of conformations that exist between basal and ligand-activated receptor, clearly demonstrated by the changes in internalization and basal activation, which may or may not be linked to dimerization. Previous studies, however, have demonstrated that the dimerization of B1AR and B2AR is not altered upon ligand activation,[36] although



(legend on next page)



Figure 6. Model summarizing the functional alterations of each B2AR mutant

While it cannot be ruled out, with current data, it is not clear whether dimerization affects all represented processes, nor is it possible to discriminate between receptors in the di/oligomeric state and those that are monomeric at different stages.

basal associations of B2AR dimers are implicated in regulating its basal activity.[27] It is currently unclear whether the increased F49A$^{1.48}$ receptor measured intracellularly is retained following misfolding or represents an active pool of receptors. Golgi signaling has been shown to utilize a pre-existing receptor pool rather than receptors delivered from the cell surface, and nanobody studies demonstrate active B1AR localized to the Golgi membrane, activation which is independent of receptor internalization from the plasma membrane.[37] This is not apparent for the B2AR, suggesting that the data may indicate F49A$^{1.48}$ as a crucial residue involved in promoting B1AR Golgi localization that could increase the pool available for Golgi signaling.

In light of our results, we suggest that B2AR (and some other aminergic receptors) specifically conserved two residues that coevolved to maintain higher levels of cell surface expression. While this emphasizes the role of amino acids in TM1, and potentially a TM1/TM7/H8 interface, in regulating receptor trafficking, cell surface expression, and consequently sensitivity of the cells to external stimuli, it also shows a lack of involvement of interface residues in canonical receptor activation mechanisms.

Limitations of the study

Our data support a rearrangement of B2AR mutant homomers; however, a current limitation of this study is demonstrating any location-specific alterations. As BRET measures receptor interactions throughout the cell, a more localized readout is required to delineate location-specific dimerization. Nor can we say from our data whether interaction changes between receptors impact basal activity or endocytosis. In addition, the pathways uncovered in this study may not be conserved across cell types, and it is not known how these mutants would behave in other systems.

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources should be directed to the lead contact, Ogun Adebali (oadebali@sabanciuniv.edu).

Materials availability

B2AR constructs are available from Aylin Hanyaloglu (a.hanyaloglu@imperial.ac.uk) under a materials transfer agreement with Imperial College London.

Figure 5. Double mutation decreases basal activity by increasing constitutive internalization

(A and B) Cell surface expression of HEK 293 cells transiently transfected with HA-B2AR WT or mutant receptors. (A) Percent cells expressing receptor shown as fold change to the WT and (B) the amount of receptor at the plasma membrane shown as fold change to the WT. $n = 5$, one sample t test: $^{*}p < 0.05$, $^{**}p < 0.01$.

(C) Whole-cell expression of B2AR-Rluc8 mutant receptors shown as fold change to the WT receptor, n = 6–10. One-sample t test: $^{**}p < 0.01$.

(D and E) cAMP production in (D) basal and (E) isoproterenol (1 pM-10 μM, 5-min) treated HEK 293 cells transiently transfected with WT and V34A-S41A B2AR and matched for receptor expression at the plasma membrane (Figure S1).

(F) Schematic demonstrating antibody conditions for labeling endocytic/constitutively internalized receptor pools and the total pool of receptor (endocytic + biosynthetic).

(G) Confocal microscopy images of HEK 293 cells transiently transfected with HA-B2AR WT and mutant receptors, either fed live with anti-HA antibody (endocytic imaging) or incubated with anti-HA antibody post-fixation and permeabilization (endocytic + biosynthetic imaging). Representative images shown, $n = 10$ cells. Scale bars, 10 μm; inset = 3 μm.

(H) Constitutive internalization measured in HEK 293 cells transiently transfected with HA-B2AR, HA-V34A-S41A B2AR, or HA-B1AR live labeled with anti-HA antibody at 4°C with/without 1-h incubation at 37°C. Cell surface expression measured via flow cytometry. Data shown as percentage change from surface expression in cells kept at 4°C, mean ± SEM. $n = 4$. One-way ANOVA with Šídák's multiple comparisons test: $^{*}p < 0.05$; $^{**}p < 0.01$. See also Figure S1.

Data and code availability

- Microscopy data reported in this article will be shared by the lead contact upon request.
- Data, orthologous MSA, and custom code used for the generation of Figures 1 and 3 are available at: https://github.com/CompGenomeLab/B2AR_Dimer_Interface.
- Any additional information required to reanalyze the data reported in this article is available from the lead contact upon request.

ACKNOWLEDGMENTS

This study is supported by the EMBO (no: 4163 to O.A) and the BBSRC (BB/V006142/1 to A.C.H).

AUTHOR CONTRIBUTIONS

Conceptualization, A.R.W., B.S., A.C.H., and O.A.; investigation, A.R.W. , B.S., and I.E.; resources, A.C.H. and O.A.; writing – original draft, A.R.W., B.S., A.C.H., and O.A.; writing – review and editing, A.R.W., B.S., A.C.H., O.A., S.D., and I.E.; visualization, A.R.W. and B.S.; supervision, A.C.H. and O.A.; funding acquisition, A.C.H. and O.A.

DECLARATION OF INTERESTS

The authors declare no competing interests.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- EXPERIMENTAL METHODS AND STUDY PARTICIPANT DETAILS
  - Cell lines
- METHOD DETAILS
  - Identification of specifically conserved residues inside the dimerization interface
  - Plasmid constructs
  - Cell lines
  - Bioluminescence resonance energy transfer
  - Flow cytometry
  - cAMP accumulation
  - MD simulations
  - Calculation of interface contact score
  - MM-GBSA calculations
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.isci.2026.115033.

Received: September 17, 2024
Revised: September 5, 2025
Accepted: February 11, 2026
Published: February 16, 2026

REFERENCES

1. Marinissen, M.J., and Gutkind, J.S. (2001). G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol. Sci. *22*, 368–376. https://doi.org/10.1016/s0165-6147(00)01678-3.
2. Sriram, K., and Insel, P.A. (2018). G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? Mol. Pharmacol. *93*, 251–258. https://doi.org/10.1124/mol.117.111062.
3. Petaja-Repo, U.E., Hogue, M., Bhalla, S., Laperrière, A., Morello, J.-P., and Bouvier, M. (2002). Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. EMBO J. *21*, 1628–1637. https://doi.org/10.1093/emboj/21.7.1628.
4. Dong, C., Filipeanu, C.M., Duvernay, M.T., and Wu, G. (2007). Regulation of G protein-coupled receptor export trafficking. Biochim. Biophys. Acta *1768*, 853–870. https://doi.org/10.1016/j.bbamem.2006.09.008.
5. Angelotti, T., Daunt, D., Shcherbakova, O.G., Kobilka, B., and Hurt, C.M. (2010). Regulation of G-Protein Coupled Receptor Traffic by an Evolutionary Conserved Hydrophobic Signal. Traffic *11*, 560–578. https://doi.org/10.1111/j.1600-0854.2010.01033.x.
6. Hanyaloglu, A.C., and von Zastrow, M. (2008). Regulation of GPCRs by Endocytic Membrane Trafficking and Its Potential Implications. Annu. Rev. Pharmacol. Toxicol. *48*, 537–568. https://doi.org/10.1146/annurev.pharmtox.48.113006.094830.
7. Ferguson, S.S. (2001). Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. *53*, 1–24.
8. Jean-Charles, P.-Y., Kaur, S., and Shenoy, S.K. (2017). G Protein–Coupled Receptor Signaling Through β-Arrestin–Dependent Mechanisms. J. Cardiovasc. Pharmacol. *70*, 142–158. https://doi.org/10.1097/fjc.0000000000000482.
9. Gusach, A., García-Nafría, J., and Tate, C.G. (2023). New insights into GPCR coupling and dimerisation from cryo-EM structures. Curr. Opin. Struct. Biol. *80*, 102574. https://doi.org/10.1016/j.sbi.2023.102574.
10. Dale, N.C., Johnstone, E.K.M., and Pfleger, K.D.G. (2022). GPCR heteromers: An overview of their classification, function and physiological relevance. Front. Endocrinol. *13*, 931573. https://doi.org/10.3389/fendo.2022.931573.
11. Selçuk, B., Erol, I., Durdağı, S., and Adebali, O. (2022). Evolutionary association of receptor-wide amino acids with G protein–coupling selectivity in aminergic GPCRs. Life Sci. Alliance *5*, e202201439. https://doi.org/10.26508/lsa.202201439.
12. Flock, T., Hauser, A.S., Lund, N., Gloriam, D.E., Balaji, S., and Babu, M.M. (2017). Selectivity determinants of GPCR-G-protein binding. Nature *545*, 317–322. https://doi.org/10.1038/nature22070.
13. Erol, I., Cosut, B., and Durdagi, S. (2019). Toward Understanding the Impact of Dimerization Interfaces in Angiotensin II Type 1 Receptor. J. Chem. Inf. Model. *59*, 4314–4327. https://doi.org/10.1021/acs.jcim.9b00294.
14. Milligan, G., Ward, R.J., and Marsango, S. (2019). GPCR homo-oligomerization. Curr. Opin. Cell Biol. *57*, 40–47. https://doi.org/10.1016/j.ceb.2018.10.007.
15. Cai, X., Wang, D., Zhang, R., Chen, Y., and Chen, J. (2023). The transmembrane domains of GPCR dimers as targets for drug development. Drug Discov. Today *28*, 103419. https://doi.org/10.1016/j.drudis.2022.103419.
16. Cordomí, A., Navarro, G., Aymerich, M.S., and Franco, R. (2015). Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins. Trends Biochem. Sci. *40*, 548–551.
17. Milligan, G. (2007). G protein-coupled receptor dimerisation: Molecular basis and relevance to function. Biochim. Biophys. Acta *1768*, 825–835. https://doi.org/10.1016/j.bbamem.2006.09.021.
18. Johnston, J.M., Wang, H., Provasi, D., and Filizola, M. (2012). Assessing the Relative Stability of Dimer Interfaces in G Protein-Coupled Receptors. PLoS Comput. Biol. *8*, e1002649. https://doi.org/10.1371/journal.pcbi.1002649.
19. Chesley, A., Lundberg, M.S., Asai, T., Xiao, R.-P., Ohtani, S., Lakatta, E.G., and Crow, M.T. (2000). The β2-Adrenergic Receptor Delivers an Antiapoptotic Signal to Cardiac Myocytes Through Gi-Dependent Coupling to Phosphatidylinositol 3′-Kinase. Circ. Res. *87*, 1172–1179. https://doi.org/10.1161/01.RES.87.12.1172.
20. Xiao, R.-P., Zhu, W., Zheng, M., Chakir, K., Bond, R., Lakatta, E.G., and Cheng, H. (2004). Subtype-specific β-adrenoceptor signaling pathways

in the heart and their potential clinical implications. Trends Pharmacol. Sci. *25*, 358–365. https://doi.org/10.1016/j.tips.2004.05.007.

21. Zhu, W.-Z., Wang, S.-Q., Chakir, K., Yang, D., Zhang, T., Brown, J.H., Devic, E., Kobilka, B.K., Cheng, H., and Xiao, R.-P. (2003). Linkage of β1-adrenergic stimulation to apoptotic heart cell death through protein kinase A–independent activation of Ca2+/calmodulin kinase II. J. Clin. Investig. *111*, 617–625. https://doi.org/10.1172/JCI16326.
22. Baker, J.G. (2010). The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br. J. Pharmacol. *160*, 1048–1061. https://doi.org/10.1111/j.1476-5381.2010.00754.x.
23. Huang, J., Chen, S., Zhang, J.J., and Huang, X.-Y. (2013). Crystal structure of oligomeric β1-adrenergic G protein–coupled receptors in ligand-free basal state. Nat. Struct. Mol. Biol. *20*, 419–425. https://doi.org/10.1038/nsmb.2504.
24. Sawyer, G.W., Ehlert, F.J., and Shults, C.A. (2010). A Conserved Motif in the Membrane Proximal C-Terminal Tail of Human Muscarinic M_1Acetylcholine Receptors Affects Plasma Membrane Expression. J. Pharmacol. Exp. Ther. *332*, 76–86. https://doi.org/10.1124/jpet.109.160986.
25. Duvernay, M.T., Zhou, F., and Wu, G. (2004). A Conserved Motif for the Transport of G Protein-coupled Receptors from the Endoplasmic Reticulum to the Cell Surface. J. Biol. Chem. *279*, 30741–30750. https://doi.org/10.1074/jbc.m313881200.
26. Parmar, V.K., Grinde, E., Mazurkiewicz, J.E., and Herrick-Davis, K. (2017). Beta2-adrenergic receptor homodimers: Role of transmembrane domain 1 and helix 8 in dimerization and cell surface expression. Biochim. Biophys. Acta. Biomembr. *1859*, 1445–1455. https://doi.org/10.1016/j.bbamem.2016.12.007.
27. Kwon, Y., Kim, D.-H., Jeong, M.G., Hong, M.-T., Park, S., Chang, Y., Zhou, K., Park, S.-Y., Zhang, J., and Ryu, S.H. (2022). Dimerization of β2-adrenergic receptor is responsible for the constitutive activity subjected to inverse agonism. Cell Chem. Biol. *29*, 1532–1540.e5. https://doi.org/10.1016/j.chembiol.2022.09.001.
28. Krissinel, E., and Henrick, K. (2007). Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. *372*, 774–797. https://doi.org/10.1016/j.jmb.2007.05.022.
29. Zhou, Q., Yang, D., Wu, M., Guo, Y., Guo, W., Zhong, L., Cai, X., Dai, A., Jang, W., Shakhnovich, E.I., et al. (2019). Common activation mechanism of class A GPCRs. eLife *8*, e50279. https://doi.org/10.7554/elife.50279.
30. Hendrik Schmidt, J., Perslev, M., Bukowski, L., Stoklund, M., Herborg, F., Herlo, R., and Lindegaard Madsen, K. (2020). Constitutive internalization across therapeutically targeted GPCRs correlates with constitutive activity. Basic Clin. Pharmacol. Toxicol. *126*, 116–121. https://doi.org/10.1111/bcpt.13274.
31. Jean-Alphonse, F., Bowersox, S., Chen, S., Beard, G., Puthenveedu, M.A., and Hanyaloglu, A.C. (2014). Spatially restricted G protein-coupled receptor activity via divergent endocytic compartments. J. Biol. Chem. *289*, 3960–3977. https://doi.org/10.1074/jbc.M113.526350.
32. Brown, L., Deighton, N.M., Bals, S., Söhlmann, W., Zerkowski, H.-R., Michel, M.C., and Brodde, O.-E. (1992). Spare Receptors for β-Adrenoceptor-Mediated Positive Inotropic Effects of Catecholamines in the Human Heart. J. Cardiovasc. Pharmacol. *19*, 222–232.
33. Irannejad, R., Tomshine, J.C., Tomshine, J.R., Chevalier, M., Mahoney, J.P., Steyaert, J., Rasmussen, S.G.F., Sunahara, R.K., El-Samad, H., Huang, B., and Von Zastrow, M. (2013). Conformational biosensors reveal GPCR signalling from endosomes. Nature *495*, 534–538. https://doi.org/10.1038/nature12000.
34. Tsvetanova, N.G., and von Zastrow, M. (2014). Spatial encoding of cyclic AMP signaling specificity by GPCR endocytosis. Nat. Chem. Biol. *10*, 1061–1065. https://doi.org/10.1038/nchembio.1665.
35. Dijkman, P.M., Castell, O.K., Goddard, A.D., Munoz-Garcia, J.C., De Graaf, C., Wallace, M.I., and Watts, A. (2018). Dynamic tuneable G protein-coupled receptor monomer-dimer populations. Nat. Commun. *9*, 1710. https://doi.org/10.1038/s41467-018-03727-6.
36. Calebiro, D., Rieken, F., Wagner, J., Sungkaworn, T., Zabel, U., Borzi, A., Cocucci, E., Zürn, A., and Lohse, M.J. (2013). Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc. Natl. Acad. Sci. USA *110*, 743–748. https://doi.org/10.1073/pnas.1205798110.
37. Irannejad, R., Pessino, V., Mika, D., Huang, B., Wedegaertner, P.B., Conti, M., and Von Zastrow, M. (2017). Functional selectivity of GPCR-directed drug action through location bias. Nat. Chem. Biol. *13*, 799–806. https://doi.org/10.1038/nchembio.2389.
38. Lomize, M.A., Pogozheva, I.D., Joo, H., Mosberg, H.I., and Lomize, A.L. (2012). OPM database and PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res. *40*, D370–D376. https://doi.org/10.1093/nar/gkr703.
39. Jo, S., Kim, T., Iyer, V.G., and Im, W. (2008). CHARMM-GUI: A web-based graphical user interface for CHARMM. J. Comput. Chem. *29*, 1859–1865. https://doi.org/10.1002/jcc.20945.
40. Lee, J., Cheng, X., Swails, J.M., Yeom, M.S., Eastman, P.K., Lemkul, J.A., Wei, S., Buckner, J., Jeong, J.C., Qi, Y., et al. (2016). CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. J. Chem. Theory Comput. *12*, 405–413. https://doi.org/10.1021/acs.jctc.5b00935.
41. Abraham, M.J., Murtola, T., Schulz, R., Páll, S., Smith, J.C., Hess, B., and Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX *1–2*, 19–25. https://doi.org/10.1016/j.softx.2015.06.001.
42. Valdés-Tresanco, M.S., Valdés-Tresanco, M.E., Valiente, P.A., and Moreno, E. (2021). gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. J. Chem. Theory Comput. *17*, 6281–6291. https://doi.org/10.1021/acs.jctc.1c00645.
43. MacKerell, A.D., Jr., Bashford, D., Bellott, M., Dunbrack, R.L., Jr., Evanseck, J.D., Field, M.J., Fischer, S., Gao, J., Guo, H., Ha, S., et al. (1998). All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins. J. Phys. Chem. B *102*, 3586–3616. https://doi.org/10.1021/jp973084f.
44. Huang, J., Rauscher, S., Nawrocki, G., Ran, T., Feig, M., de Groot, B.L., Grubmüller, H., and MacKerell, A.D. (2017). CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods *14*, 71–73. https://doi.org/10.1038/nmeth.4067.
45. Klauda, J.B., Venable, R.M., Freites, J.A., O'Connor, J.W., Tobias, D.J., Mondragon-Ramirez, C., Vorobyov, I., MacKerell, A.D., Jr., and Pastor, R.W. (2010). Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types. J. Phys. Chem. B *114*, 7830–7843. https://doi.org/10.1021/jp101759q.
46. Beglov, D., and Roux, B. (1994). Finite representation of an infinite bulk system: Solvent boundary potential for computer simulations. J. Chem. Phys. *100*, 9050–9063. https://doi.org/10.1063/1.466711.
47. Berendsen, H.J.C., Postma, J.P.M., van Gunsteren, W.F., DiNola, A., and Haak, J.R. (1984). Molecular dynamics with coupling to an external bath. J. Chem. Phys. *81*, 3684–3690. https://doi.org/10.1063/1.448118.
48. Parrinello, M., and Rahman, A. (1980). Crystal Structure and Pair Potentials: A Molecular-Dynamics Study. Phys. Rev. Lett. *45*, 1196–1199. https://doi.org/10.1103/PhysRevLett.45.1196.
49. Hoover, W.G. (1986). Constant-pressure equations of motion. Phys. Rev. A Gen. Phys. *34*, 2499–2500. https://doi.org/10.1103/PhysRevA.34.2499.
50. Onufriev, A., Bashford, D., and Case, D.A. (2004). Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins *55*, 383–394. https://doi.org/10.1002/prot.20033.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-HA.11 Epitope Tag	Biolegend	901502; RRID:AB_2565007
Critical commercial assays		
cAMP dynamic kit	Cisbio	62AM4PEB
Experimental models: Cell lines		
HEK 293	ATCC	CRL-1573; RRID:CVCL_0045
Recombinant DNA		
HA-B2AR-Rluc8	Johnathan Javitch	NA
HA-B2AR-Rluc8 S41A variant	This manuscript	NA
HA-B2AR-Rluc8 V34A variant	This manuscript	NA
HA-B2AR-Rluc8 V34A-S41A variant	This manuscript	NA
HA-B2AR-Rluc8 F49A variant	This manuscript	NA
B2AR-Venus	Johnathan Javitch	NA
B2AR-Venus S41A variant	This manuscript	NA
B2AR-Venus V34A variant	This manuscript	NA
B2AR-Venus F49A variant	This manuscript	NA
B2AR-Venus V34A-S41A variant	This manuscript	NA
HA-B1AR	Mark von Zastrow	NA
Software and algorithms		
PISA server (Protein Interfaces, Surfaces and Assemblies)	Krissinel & Henrick[28]	
PyMOL Molecular Graphics System	Schrödinger, LLC	
OPM/PPM server (Orientations of Proteins in Membranes/ Positioning of Proteins in Membranes)	Lomize et al.[38]	
CHARMM-GUI Membrane Builder	Jo et al.[39]; Lee et al.[40]	
GROMACS	Abraham et al.[41]	
gmx_MMPBSA	Valdés-Tresanco et al.[42]	
Residue-residue contact score algorithm	Zhou et al.[29]	

EXPERIMENTAL METHODS AND STUDY PARTICIPANT DETAILS

Cell lines

HEK 293 culture and transfection

HEK 293 cells (female) were maintained in DMEM containing 10% fetal bovine serum and 100 U/ml penicillin-streptomycin and cultured in 75 cm flasks at 37°C in 95% air and 5% CO2. Cells were routinely checked for mycoplasma. Cells at 90% confluency were passaged using 0.25% trypsin with 0.02% EDTA in phosphate-buffered saline. HEK 293 cells were transfected using Lipofectamine 2000 (Invitrogen) in DMEM containing 10% FBS without antibiotics for 48h. HEK 293 cells were not authenticated internally but were purchased from ATCC and used as initially authenticated by the vendor.

METHOD DETAILS

Identification of specifically conserved residues inside the dimerization interface

We started our analysis by identifying the interface residues of turkey B1AR dimer (PDB ID: 4GPO)[23] by using the PISA online server available at https://www.ebi.ac.uk/pdbe/pisa/.[28] Next, we retrieved the multiple sequence alignment including aminergic receptors and their one to one orthologs from our previous work.[11] 70 orthologs were used for B1AR, 77 for B2AR and, 67 for B3AR. We then determined the conservation percentages for the residues of human BARs within their orthologs by determining the most frequently observed amino acid and other amino acids similar to that with a BLOSUM80 score greater than 1. The conservation percentage for

an MSA column is calculated as the total count of the most frequently conserved amino acid and the similar ones, divided by total number of non-gap amino acids. BLOSUM (BLOcks SUbstitution Matrix) is a scoring matrix that shows the likelihood of amino acid substitutions in protein sequences during evolution. BLOSUM80 is the substitution matrix designed for proteins with 80% average identity. The BLOSUM80 scoring matrix is available at: https://www.ncbi.nlm.nih.gov/IEB/ToolBox/C_DOC/lxr/source/data/BLOSUM80. Based on their conservation scores in β-adrenergic receptor subtypes we have divided positions into two categories: If a position is conserved in every receptor with a similar (BLOSUM 80 score higher than 1) amino acid more than 90%, we labeled that position as "consensus". We made a single exception for B1AR L70. If a position is conserved in a single receptor is conserved with a non-similar amino acid with more than 90%, we designated that position as "specifically conserved for receptor X".

Plasmid constructs

HA-B1AR was kindly gifted by Mark von Zastrow. Wild type Venus-B2AR and wild-type HA-Rluc8-B2AR were kindly provided by Kevin Pfleger and Jonathon Javitch, respectively. From these constructs mutations at the appropriate sites were introduced using QuikChange site-directed mutagenesis (Agilent).

Cell lines

HEK 293 cells (ATCC) were maintained in DMEM with phenol red (Sigma), 10% fetal bovine serum (Sigma), and 100 U/mL penicillin-streptomycin. Cells were cultured in 75 cm flasks at 37°C in 5% CO2 and were passaged upon reaching 80–90% confluency, using 0.25% trypsin with 0.02% EDTA in phosphate-buffered saline. Cells were transfected using lipofectamine 2000 (Invitrogen) in DMEM with phenol red 10% fetal bovine serum for 48-h before experiments.

Bioluminescence resonance energy transfer

ADBR2 wild-type and mutant homomers were measured using BRET in transiently transfected HEK 293 cells. Cells were transfected with 200 ng B2AR Rluc8 and increasing amounts of B2AR Venus (0–700 ng). After 48 h cells were lifted manually in PBS and plated in opaque white 96 well plates. Coelenterazine-h was added to a final concentration of 5 μM and Emission was measured at 488 nm and 530 nm using an FLUOstar spectrofluorometer. Venus YFP was measured via excitation at 485 nm and emission at 540 nm. Using non-linear regression, the BRET curve was plotted as Net BRET signal (acceptor/donor emission ratio, corrected for the background signal) against the ratio of acceptor to donor.

Flow cytometry

Plasma membrane expression of receptors was measured using HEK 293 cells transiently transfected with B2AR wild-type or mutant HA-tagged receptor. 48 h later cells were live fed with anti-HA antibody (Biolegend) for 20-min at 37 °C, washed 3 times with PBS before 1-h incubation with Alexa Fluor 488 (Invitrogen) on ice. Cells were washed three times before fluorescence was measured using a FACS Calibur flow cytometer.

For measurement of constitutive internalization cells were labeled with primary anti-HA antibody for 1-h at 4 °C Celsius before 3 times washing with PBS and incubation of one set of cells at 37 °C for 1-h to allow constitutive internalization to resume. All cells were then labeled with Alexa Fluor 488 for 1 h at 4 °C before cells were washed and fluorescence was measured using a FACS Calibur flow cytometer.

cAMP accumulation

HEK 293 cells transiently expressing wild-type and mutant B2AR were plated in 96 well plates at a density of 50,000 cells per well. 24 h after plating cells were incubated with isoproterenol (1 pM-10 μM) in PBS for 5-min. Cells were lysed in Cisbio lysis buffer, centrifuged for 15 min at 16,000g and assayed as per manufacturers protocol (Cisbio Gαs dynamic assay) using a PHERAstar FSX equipped with an HTRF optic module.

MD simulations

The X-ray structure of inactive state of the B2AR was retrieved from Protein DataBank (PDB) with the PDB ID: 4GBR.[29] For TM1/TM7/H8 dimerization interface, crystal structure of B1AR was used, which deposited to PDB in homo 2-mer global stoichiometry (PDB ID: 4GPO.[23] Each B2AR monomer aligned to 4GPO to obtain dimeric assembly. Obtained dimeric B2AR dimeric structure labeled as WT, then using PyMol, following alanine mutations were introduced, V34A$^{1.33}$, S41A$^{1.40}$, V34A-S41A, and F49A$^{1.48}$ (The PyMOL Molecular Graphics System, Version 2.1 Schrödinger, LLC.). Three mutations that introduced to thermostabilize the protein was mutated back to WT (T96M, T98M, and E187N). Prepared structures were submitted to Orientations of Proteins in Membranes (OPM) (https://opm.phar.umich.edu/) to find the orientations of dimeric structures in the lipid bilayer.[38] CHARMM-GUI web-server was used to generate inputs for the MD simulations.[39,40] Since the truncated version of the B2AR (from both terminals) was used, N-terminus and C-terminus cappings were added. In simulations, POPC lipid type, and TIP3P water model[43] were used, and simulation box neutralized with 0.15 M NaCl. For the ions, lipids, and proteins CHARMM36m force field was used.[44–46] Six equilibration steps were applied to reach 50 ns equilibration time before the production run (5, 5, 10, 10, 10, and 10 ns). Berendsen thermostat and barostat applied in equilibration steps.[47] Production simulations were 500 ns and repeated at least 5 times using Parrinello-Rahman barostat[48] and

Nosé–Hoover thermostat.[49] Gromacs version 2020 was used in simulations, and for the simulation trajectories 5000 frames were recorded for each replica, in total 25000 frames were collected.[41]

Calculation of interface contact score

We retrieved frames with 50ns intervals with each other from MD simulations of inactive-inactive WT and mutated B2ARs from each replicate. We employed RRCS (Residue-Residue Contact Score) algorithm[29] to calculate RRCSs for every residue pair within the dimerization interface. For each frame we calculated the total RRCS by summing up RRCSs of the residues inside the dimerization interface and called it interface contact score. To identify potential changes induced by different mutations, we used one-way ANOVA followed by Tukey's Honest Significant Difference (HSD) post-hoc test to compare the interface contact scores of across simulations for each tested variant. padj<0.01 was considered as significant for this analysis.

MM-GBSA calculations

For MM-GBSA calculations, 30,000 frames were used for WT and 25,000 for the other mutants. First, all frames were concatenated to obtain one single trajectory. Then, gmx_MMPBSA v1.6.4[42] was used to calculate the interaction energies between protomers (chain A and chain B). The GB-OBC2 model was used for the calculations (igb = 5).[50] The per-residue energy decomposition was analyzed by adding 1–4 EEL to EEL and 1–4 VDW to VDW potential terms (idecomp = 2).

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical data analyses were performed in GraphPad Prism 8. In cases of multiple comparison one-way ANOVA was used with either Tukey's post-hoc test when comparing every mean with every other mean or Sidak's post-hoc test when comparing a select set of means. For interface contact score calculations one-way ANOVA was followed by Tukey's Honest Significant Difference (HSD) post-hoc test. padj<0.01 was considered as significant for this analysis. In cases where data had been normalized to basal or agonist response, one-sample *t* test was performed to allow comparison against a bounded value. For each test, $p < 0.05$ was considered significant. Detail of specific tests can be found in the figure legends.